» Articles » PMID: 21903062

Midwall Fibrosis is an Independent Predictor of Mortality in Patients with Aortic Stenosis

Abstract

Objectives: The goal of this study was to assess the prognostic significance of midwall and infarct patterns of late gadolinium enhancement (LGE) in aortic stenosis.

Background: Myocardial fibrosis occurs in aortic stenosis as part of the hypertrophic response. It can be detected by LGE, which is associated with an adverse prognosis in a range of other cardiac conditions.

Methods: Between January 2003 and October 2008, consecutive patients with moderate or severe aortic stenosis undergoing cardiovascular magnetic resonance with administration of gadolinium contrast were enrolled into a registry. Patients were categorized into absent, midwall, or infarct patterns of LGE by blinded independent observers. Patient follow-up was completed using patient questionnaires, source record data, and the National Strategic Tracing Service.

Results: A total of 143 patients (age 68 ± 14 years; 97 male) were followed up for 2.0 ± 1.4 years. Seventy-two underwent aortic valve replacement, and 27 died (24 cardiac, 3 sudden cardiac deaths). Compared with those with no LGE (n = 49), univariate analysis revealed that patients with midwall fibrosis (n = 54) had an 8-fold increase in all-cause mortality despite similar aortic stenosis severity and coronary artery disease burden. Patients with an infarct pattern (n = 40) had a 6-fold increase. Midwall fibrosis (hazard ratio: 5.35; 95% confidence interval: 1.16 to 24.56; p = 0.03) and ejection fraction (hazard ratio: 0.96; 95% confidence interval: 0.94 to 0.99; p = 0.01) were independent predictors of all-cause mortality by multivariate analysis.

Conclusions: Midwall fibrosis was an independent predictor of mortality in patients with moderate and severe aortic stenosis. It has incremental prognostic value to ejection fraction and may provide a useful method of risk stratification.

Citing Articles

Pro-Fibrotic Macrophage Subtypes: SPP1+ Macrophages as a Key Player and Therapeutic Target in Cardiac Fibrosis?.

Uhlig M, Billig S, Wienhold J, Schumacher D Cells. 2025; 14(5).

PMID: 40072075 PMC: 11898914. DOI: 10.3390/cells14050345.


Comparative Assessment of CMR-Determined Extracellular Volume Metrics in Predicting Adverse Outcomes.

Mascherbauer K, Kronberger C, Dona C, Koschutnik M, Dannenberg V, Poledniczek M J Clin Med. 2025; 14(2.

PMID: 39860388 PMC: 11765513. DOI: 10.3390/jcm14020382.


Elevated septal native T1 time in cardiac magnetic resonance imaging suggesting myocardial fibrosis in young kidney transplant recipients.

Ubenauf T, von der Born J, Sugianto R, Grabitz C, Lehmann E, Memaran N J Cardiovasc Magn Reson. 2025; 27(1):101839.

PMID: 39814266 PMC: 11870264. DOI: 10.1016/j.jocmr.2025.101839.


Moderate Aortic Stenosis With Cardiac Damage: A New Type of Severe Aortic Stenosis.

Mihatov N, Pibarot P Struct Heart. 2024; 8(6):100336.

PMID: 39670048 PMC: 11632786. DOI: 10.1016/j.shj.2024.100336.


Quantification of Replacement Fibrosis in Aortic Stenosis: A Narrative Review on the Utility of Cardiovascular Magnetic Resonance Imaging.

Rajah M, Doubell A, Herbst P Diagnostics (Basel). 2024; 14(21).

PMID: 39518402 PMC: 11544846. DOI: 10.3390/diagnostics14212435.